Mutation in the Hepatitis E Virus Polymerase and Outcome of Ribavirin Therapy.

ABSTRACT: Hepatitis E virus (HEV) can lead to chronic infection in solid-organ transplant patients. Ribavirin is efficient for treatment of chronically infected patients. Recently, the1634R mutation in the HEV polymerase has been associated with treatment failure. However, it is unclear if this mutation can be used as a prognostic marker of treatment outcome. We studied the prevalence of the 1634R mutation in the HEV polymerase of patients starting ribavirin therapy, the influence of the 1634R variants on the viral response, the frequency of the 1634R mutation in patients whose treatment failed, and its impact on ribavirin retreatment. We analyzed pretreatment samples from 63 solid-organ transplant patients with chronic hepatitis E using deep sequencing; 42 patients had a sustained virologic respons

SUBMITTER: Lhomme S 

PROVIDER: S-EPMC4775994 | biostudies-literature | 2015 Dec

REPOSITORIES: biostudies-literature